Hearse D J, Erol C, Robinson L A, Maxwell M P, Braimbridge M V
J Thorac Cardiovasc Surg. 1985 Mar;89(3):428-38.
We have characterized an isolated rat heart preparation in which particles induce transient coronary vasoconstriction. Exploiting the fact that all commercially available intravenous solutions contain permissible levels of contaminant particles (usually 2 to 20 micron in diameter), we investigated whether these particles have any adverse effect upon coronary flow. A commercially available intravenous solution was modified to produce the St. Thomas' Hospital cardioplegic solution. Constant-pressure infusion of this solution over a 20 minute period caused a 46.2% +/- 5.1% reduction in coronary flow. This flow impairment could be limited to 13.3% +/- 3.5% by the incorporation of a 0.8 micron in-line filter. In hearts perfused with particle-containing solution followed by ultrafiltered solutions, the impairment of coronary flow was reversed within 1 minute. This quick reversal indicates that the particles were impairing flow not by physical occlusion of vessels but by triggering some form of transient vasoconstriction. In studies with filters of varying porosity (between 0.8 and 15.0 micron), the phenomenon was shown to be attributable to relatively small numbers of particles greater than 10.0 micron in diameter. In studies of myocardial protection, it was shown that the impairment of solution delivery and distribution caused by particles could severely reduce the protective properties of a chemical cardioplegic solution; hearts subjected to 180 minutes of hypothermic (20 degrees C) ischemic arrest with multidose (3 minutes every 30 minutes) cardioplegia recovered almost completely upon reperfusion if a filtered (0.8 micron) solution was used, but failed to recover when unfiltered, commercially prepared solutions were used. In an attempt to define the mechanisms underlying the particle-induced vasoconstriction, we conducted dose-response studies in which various vasoactive agents were used in an attempt to combat the effects of the particles. At their optimal concentrations, procaine (10.0 mmol/L), nifedipine (0.1 mumol/L), and adenosine triphosphate (1.0 mmol/L) completely prevented the problem; lidocaine and dipyridamole partially alleviated the effect; verapamil and isosorbide dinitrate were ineffective. These results indicate that several mechanisms acting at a small vessel level might contribute to the particle-induced vasoconstriction.
我们已对一种离体大鼠心脏标本进行了特性描述,在该标本中颗粒可引起短暂的冠状动脉血管收缩。利用所有市售静脉注射液都含有允许水平的污染物颗粒(通常直径为2至20微米)这一事实,我们研究了这些颗粒是否对冠状动脉血流有任何不利影响。将一种市售静脉注射液进行改良,制成了圣托马斯医院心脏停搏液。在20分钟内恒压输注该溶液导致冠状动脉血流减少46.2%±5.1%。通过加入一个0.8微米的在线过滤器,这种血流损害可限制在13.3%±3.5%。在用含颗粒溶液灌注后再用超滤溶液灌注的心脏中,冠状动脉血流的损害在1分钟内得到逆转。这种快速逆转表明颗粒损害血流并非通过物理性阻塞血管,而是通过触发某种形式的短暂血管收缩。在使用不同孔隙率(0.8至15.0微米之间)过滤器的研究中,该现象表明是由于相对少量直径大于10.0微米的颗粒所致。在心肌保护研究中,结果表明颗粒引起的溶液输送和分布受损可严重降低化学心脏停搏液的保护特性;如果使用经过过滤(0.8微米)的溶液,在低温(20摄氏度)缺血停搏180分钟并多次给药(每30分钟3分钟)心脏停搏液后再灌注时,心脏几乎能完全恢复,但使用未过滤的市售制剂时则无法恢复。为了确定颗粒诱导血管收缩的潜在机制,我们进行了剂量反应研究,其中使用了各种血管活性药物来试图对抗颗粒的影响。在其最佳浓度下,普鲁卡因(10.0毫摩尔/升)、硝苯地平(0.1微摩尔/升)和三磷酸腺苷(1.0毫摩尔/升)完全预防了该问题;利多卡因和双嘧达莫部分减轻了这种影响;维拉帕米和硝酸异山梨酯无效。这些结果表明,在小血管水平起作用的几种机制可能导致了颗粒诱导的血管收缩。